Welcome to our dedicated page for Xtant Medical news (Ticker: XTNT), a resource for investors and traders seeking the latest updates and insights on Xtant Medical stock.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) is a leader in the field of regenerative medicine and surgical solutions for spinal disorders. The company designs, develops, and markets a comprehensive range of orthobiologics and spinal implant systems to aid spinal fusion in complex spine, deformity, and degenerative procedures. Their offerings are widely utilized by orthopedic spine surgeons and neurosurgeons for treating various spinal disorders across cervical, thoracolumbar, and interbody regions.
Xtant Medical's product portfolio includes notable biomaterial products such as OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the 3Demin line. These products are essential for promoting bone healing, and their applications extend to orthopedic disorders and cranial, foot, and ankle surgeries. The company's innovative solutions are distributed in both domestic and international markets, making a significant impact on global neurological and orthopedic surgery markets.
In recent developments, Xtant Medical has successfully raised its 2023 annual revenue guidance to $88 million - $91 million. Furthermore, the company has projected its full-year 2024 revenue guidance between $112 million - $116 million, signifying strong growth and operational efficiency. The financial results for the first quarter of 2024 were impressive, with total revenue reaching $27.9 million, an increase of 55% compared to the previous year. This growth was driven by strategic acquisitions, increased independent agent sales, and additional product sales.
Xtant Medical is dedicated to honoring the gift of donation, enabling patients to live full and complete lives. The team at Xtant is composed of dedicated and talented individuals who operate with the highest integrity to serve their customers. The company's mission and values are reflected in their continuous innovation and commitment to providing high-quality medical solutions.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) reported financial results for the fourth quarter and full year ended December 31, 2021. The company achieved 4% year-over-year revenue growth, totaling $55.3 million for 2021, driven by private label and OEM orthobiologics sales. The fourth quarter revenue remained stable at $14.0 million. However, gross margin decreased to 55.1% from 64.1% in Q4 2020. Operating expenses rose to $9.6 million in Q4. The net loss for the year improved to $4.8 million, compared to $7.0 million in 2020.
Xtant Medical Holdings (NYSE American: XTNT) will release its financial results for Q4 and the full year ending December 31, 2021, on March 8, 2022, before market open. CEO Sean Browne and Interim CFO Scott Neils will discuss the results in a conference call scheduled for the same day at 9:00 AM ET. Investors can access the call by dialing 877-407-6184 or internationally at 201-389-0877. A replay will be available on their website post-call.
Xtant Medical Holdings, a global medical technology company specializing in spinal disorder solutions, announced that CEO Sean Browne will present at the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. A pre-recorded presentation will be available on the company's website starting January 10, 2022, at 7:00 AM Eastern Time and will remain accessible for 30 days. Xtant focuses on designing and commercializing orthobiologics and spinal implant systems for complex spinal procedures.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) has appointed Scott Neils as Interim Chief Financial Officer, effective January 3, 2022. Neils, who has 15 years of experience in public accounting and corporate finance, previously served as the Company’s Controller since August 2019. His promotion follows the tenure of Greg Jensen, who has led the finance team for nearly three years. Neils' extensive experience in finance will be pivotal for the Company as it continues to focus on surgical solutions for spinal disorders, ensuring stability during this transitional phase.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) reported third quarter 2021 financial results, noting a revenue of $13.8 million, a slight decrease from $14.0 million in the prior-year period. The company experienced a net loss of $1.8 million, up from a loss of $1.4 million year-over-year. Gross margin also declined to 52.2% from 66.0%, attributed to changes in sales mix and increased write-downs of excess inventory. Operating expenses rose to $8.6 million due to higher salaries and marketing costs. Xtant continues to expand its distribution network despite challenges from the COVID-19 delta variant.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) will announce its Q3 financial results for the period ending September 30, 2021, on November 12, 2021, prior to market opening. A conference call featuring Sean Browne, President and CEO, and Greg Jensen, CFO, is scheduled for 9:00 AM ET the same day. Investors can listen to the call via dial-in or webcast. Xtant Medical specializes in surgical solutions for spinal disorders and offers a range of orthobiologics and spinal implant systems.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) announced that CEO Sean Browne will present at the H.C. Wainwright 23rd Annual Global Investment Conference, scheduled for September 13-15, 2021. A pre-recorded presentation will be available on the company's website starting September 13, 2021, at 7:00 AM Eastern Time and will remain accessible for 90 days. Xtant Medical focuses on developing and commercializing spinal implant systems and orthobiologics for spinal fusion.
Xtant Medical Holdings, focused on surgical solutions for spinal disorders, reported a 42% revenue increase to $15.0 million for Q2 2021 compared to the previous year. The gross margin improved to 63.5% from 62.2%. The net loss shrank to $0.7 million or $0.01 per share, significantly better than the $2.5 million loss in Q2 2020. The company closed a $20 million debt refinancing and reported a Non-GAAP Adjusted EBITDA of $0.9 million. Xtant's expansion in sales force and distribution aims to enhance future growth.
Xtant Medical Holdings, Inc. (XTNT) will release its financial results for Q2 2021 on August 5, 2021, before the market opens. The conference call will be hosted by CEO Sean Browne and CFO Greg Jensen at 9:00 AM ET, providing insights into the company’s performance in the spinal disorder market. Investors can access the call via dial-in or webcast, with a replay available on their website.
FAQ
What is the current stock price of Xtant Medical (XTNT)?
What is the market cap of Xtant Medical (XTNT)?
What does Xtant Medical Holdings, Inc. specialize in?
Which products are part of Xtant Medical's portfolio?
What are the recent financial achievements of Xtant Medical?
Who are the primary users of Xtant Medical's products?
What recent business highlights has Xtant Medical reported?
Where can I find more information about Xtant Medical?
How does Xtant Medical contribute to patient care?
What are Xtant Medical's core competencies?
How can I contact Xtant Medical for investor relations?
What is the mission of Xtant Medical?
